Published in Circulation on February 08, 2010
Treatment With Tamoxifen in Cryptococcal Meningitis | NCT03112031
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Considerations on safety concerns about citalopram prescribing. Mayo Clin Proc (2012) 1.97
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. Crit Care Med (2016) 1.88
Bi-stable wave propagation and early afterdepolarization-mediated cardiac arrhythmias. Heart Rhythm (2011) 1.71
Pro- and antiarrhythmic effects of ATP-sensitive potassium current activation on reentry during early afterdepolarization-mediated arrhythmias. Heart Rhythm (2012) 1.42
Insights into the problem of alarm fatigue with physiologic monitor devices: a comprehensive observational study of consecutive intensive care unit patients. PLoS One (2014) 1.32
An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia. J Cardiovasc Electrophysiol (2013) 1.31
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf (2013) 1.24
Magnesium in Prevention and Therapy. Nutrients (2015) 1.11
Magnesium in disease. Clin Kidney J (2012) 1.00
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott) (2016) 0.97
Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf (2012) 0.94
Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy. Korean J Anesthesiol (2013) 0.90
Synchronization of early afterdepolarizations and arrhythmogenesis in heterogeneous cardiac tissue models. Biophys J (2012) 0.89
Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf (2011) 0.88
Prediction of 90-day mortality in patients without diabetes by severe hypoglycemia: blood glucose level as a novel marker of severity of underlying disease. Acta Diabetol (2014) 0.86
Utility of the electrocardiogram in drug overdose and poisoning: theoretical considerations and clinical implications. Curr Cardiol Rev (2012) 0.84
Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused? Cleve Clin J Med (2013) 0.84
The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules (2015) 0.83
QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. J Anesth (2013) 0.83
Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. Med Mycol Case Rep (2014) 0.82
Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol (2015) 0.82
Unnecessary arrhythmia monitoring and underutilization of ischemia and QT interval monitoring in current clinical practice: baseline results of the Practical Use of the Latest Standards for Electrocardiography trial. J Electrocardiol (2010) 0.81
A Wavelet-Based Algorithm for Delineation and Classification of Wave Patterns in Continuous Holter ECG Recordings. Comput Cardiol (2010) (2010) 0.81
Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc (2016) 0.80
Marked QTc Prolongation and Torsades de pointes in Patients with Chronic Inflammatory Arthritis. Front Cardiovasc Med (2016) 0.79
Analysis of Orders for QTc-Prolonging Medication for Intensive and Cardiac Care Unit Patients with Pre-existing QTc Prolongation (QTIPPP Study). Can J Hosp Pharm (2011) 0.79
A systematic review of the cardiotoxicity of methadone. EXCLI J (2015) 0.79
Static and Dynamic Electrocardiographic Patterns Preceding Torsades de Pointes in the Acquired and Congenital Long QT Syndrome. Comput Cardiol (2010) (2010) 0.78
Don't fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert. J Am Med Inform Assoc (2014) 0.78
Remote noninvasive allograft rejection monitoring for heart transplant recipients: study protocol for the novel evaluation with home electrocardiogram and remote transmission (NEW HEART) study. BMC Cardiovasc Disord (2012) 0.78
Knowledge and practices of Thai emergency physicians regarding the care of delirious elderly patients. Int J Emerg Med (2014) 0.78
Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls. Lupus Sci Med (2016) 0.76
Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. Clin Kidney J (2014) 0.76
Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center. Hosp Pharm (2016) 0.75
[Not Available]. Can J Hosp Pharm (2016) 0.75
Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright? Can J Hosp Pharm (2016) 0.75
Propofol-associated QTc prolongation. Ther Adv Drug Saf (2016) 0.75
Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol (2017) 0.75
Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings. J Toxicol Pathol (2010) 0.75
Overdrive pacing in a patient with incessant torsades de pointes. BMJ Case Rep (2013) 0.75
Hyperglycemia is associated with corrected QT prolongation and mortality in acutely ill patients. J Cardiovasc Nurs (2014) 0.75
Effect of Dexmedetomidine on Heart Rate-Corrected QT and Tpeak-Tend Intervals During Robot-Assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position: A Prospective, Randomized, Double-Blinded, Controlled Study. Medicine (Baltimore) (2016) 0.75
Serum Calcium and Risk of Sudden Cardiac Arrest in the General Population. Mayo Clin Proc (2017) 0.75
Cardiac Monitoring in the Emergency Department. Crit Care Nurs Clin North Am (2016) 0.75
Reduced functional connectivity between ventromedial prefrontal cortex and insula relates to longer corrected QT interval in HIV+ and HIV- individuals. Clin Neurophysiol (2017) 0.75
Drug-Induced QT Prolongation And Torsades de Pointes. P T (2017) 0.75
Phenotype of Children with QT Prolongation Identified Using an Institution-Wide QT Alert System. Pediatr Cardiol (2015) 0.75
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 10.18
Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med (2009) 7.89
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell (1995) 7.73
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 5.49
QTc interval screening in methadone treatment. Ann Intern Med (2009) 5.23
Torsade de pointes associated with very-high-dose methadone. Ann Intern Med (2002) 4.78
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (2002) 4.40
[Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss (1966) 4.21
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
The long QT syndrome. Prospective longitudinal study of 328 families. Circulation (1991) 3.99
Approaches to sudden death from coronary heart disease. Circulation (1971) 3.58
Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med (1998) 3.41
Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA (1993) 2.78
Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc (2003) 2.69
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet (1999) 2.48
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med (2006) 2.37
Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation (2005) 2.25
Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology (2007) 2.23
Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol (2002) 2.19
Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation (2004) 2.09
Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm (2005) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation (1996) 2.04
Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol (2007) 2.04
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Genetics of acquired long QT syndrome. J Clin Invest (2005) 1.96
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm (2007) 1.93
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Overrepresentation of the proarrhythmic, sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. Heart Rhythm (2008) 1.87
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest (2006) 1.79
Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) (2003) 1.78
Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res (1993) 1.78
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf (2008) 1.73
Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol (2006) 1.73
The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol (2007) 1.69
Rate-corrected QT interval: techniques and limitations. Am J Cardiol (1993) 1.68
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand (2005) 1.60
Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol (1983) 1.58
What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol (2002) 1.54
Cardiac actions of erythromycin: influence of female sex. JAMA (1998) 1.53
Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis (2002) 1.50
The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med (2006) 1.48
Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm (2008) 1.37
Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation (1997) 1.31
Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health (1998) 1.21
Torsades de pointes induced by erythromycin. Chest (1994) 1.20
How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.19
In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol (2006) 1.19
Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol (1990) 1.17
Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf (2001) 1.15
Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res (1984) 1.14
Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J (2006) 1.12
Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol (2006) 1.12
QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev (2002) 1.10
Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm (2005) 1.09
T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol (1994) 1.08
Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol (2001) 1.05
Drug induced QT prolongation. Cardiol J (2007) 1.03
Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med (1987) 1.02
Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med (1999) 1.01
Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome. J Electrocardiol (2008) 1.00
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther (1991) 1.00
Ibutilide. Circulation (1998) 0.99
Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J (1993) 0.97
Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol (2008) 0.97
Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol (2008) 0.97
How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods (2003) 0.96
Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol (1996) 0.95
Amiodarone and torsade de pointes. Ann Intern Med (1989) 0.95
Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf (2006) 0.94
Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol (1998) 0.93
Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol (1993) 0.91
Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol (2006) 0.89
Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol (2003) 0.89
[The value of magnesium in intensive care medicine]. Z Kardiol (1994) 0.88
Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I. Int J Cardiol (2006) 0.87
Torsades de pointes induced by antibiotics. Eur J Intern Med (2006) 0.87
Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol (2007) 0.86
Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses (2006) 0.86
Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation. Crit Care Nurs Clin North Am (2006) 0.86
Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther (1997) 0.85
Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. J Electrocardiol (2004) 0.85
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Universal definition of myocardial infarction. Circulation (2007) 11.69
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Engineering and algorithm design for an image processing Api: a technical report on ITK--the Insight Toolkit. Stud Health Technol Inform (2002) 4.65
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2012) 4.45
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm (2005) 4.21
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation (2006) 3.50
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 3.47
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation (2010) 3.35
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation (2006) 3.23
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm (2009) 3.14
Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation (2009) 3.11
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Anesthesia for patients with congenital long QT syndrome. Anesthesiology (2005) 2.85
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation (2013) 2.82
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm (2009) 2.81
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc (2008) 2.80
Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A (2008) 2.79
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab (2005) 2.72
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 2.68
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm (2007) 2.62
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2010) 2.62
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol (2006) 2.59
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation (2008) 2.56
Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation (2013) 2.56
Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J (2005) 2.55
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation (2008) 2.54
Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest (2008) 2.54
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation (2007) 2.50
Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci U S A (2007) 2.49
Cardiopulmonary resuscitation quality: [corrected] improving cardiac resuscitation outcomes both inside and outside the hospital: a consensus statement from the American Heart Association. Circulation (2013) 2.49
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation (2007) 2.42
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41